세계 자가 줄기세포 및 비 줄기세포 기반 치료 시장 : 유형, 적응증, 최종 사용자별 예측(2024년-2030년)

[180 Pages Report] The Autologous Stem Cell & Non-Stem Cell Based Therapies Market size was estimated at USD 7.17 billion in 2023 and expected to reach USD 8.22 billion in 2024, at a CAGR 14.78% to reach USD 18.83 billion by 2030.

Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autologous Stem Cell & Non-Stem Cell Based Therapies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market, highlighting leading vendors and their innovative profiles. These include Brainstorm Cell Therapeutics, Inc., Castle Creek Biosciences Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences, Inc., HCA International Limited, Hemogenyx Pharmaceuticals PLC, Hemostemix Inc., Jasper Therapeutics, Inc., NOVADIP Biosciences S.A., Novartis AG, Opexa Therapeutics, Inc., Regeneus Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Autologous Stem Cell & Non-Stem Cell Based Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Autologous Non-Stem Cells
  • Autologous Stem Cells
• Indication
  • Cancer
  • Cardiovascular Disease
  • Neurodegenerative Disorders
  • Orthopedic Diseases
• End-User
  • Ambulatory Surgical Centers
  • Hospitals
  • Research Facilities
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

3. What are the technology trends and regulatory frameworks in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

4. What is the market share of the leading vendors in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

5. Which modes and strategic moves are suitable for entering the Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence of cancer and diabetes among population
    • 5.1.1.2. Increased demand to manage a large number of infectious diseases
    • 5.1.1.3. Advantage of intensive therapy for older patients
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with autologous stem cell & non-stem cell therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in investment for extensive research and development
    • 5.1.3.2. Advances in treating various diseases, neurodegenerative diseases and macular degeneration
  • 5.1.4. Challenges
    • 5.1.4.1. Risks and complications associated with the therapy
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by Type

• 6.1. Introduction
• 6.2. Autologous Non-Stem Cells
• 6.3. Autologous Stem Cells

7. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular Disease
• 7.4. Neurodegenerative Disorders
• 7.5. Orthopedic Diseases

8. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Research Facilities

9. Americas Autologous Stem Cell & Non-Stem Cell Based Therapies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Autologous Stem Cell & Non-Stem Cell Based Therapies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Stem Cell & Non-Stem Cell Based Therapies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

• 13.1. Key Company Profiles
  • 13.1.1. Brainstorm Cell Therapeutics, Inc.
  • 13.1.2. Castle Creek Biosciences Inc.
  • 13.1.3. Cytori Therapeutics Inc.
  • 13.1.4. Dendreon Pharmaceuticals LLC
  • 13.1.5. Gilead Sciences, Inc.
  • 13.1.6. HCA International Limited
  • 13.1.7. Hemogenyx Pharmaceuticals PLC
  • 13.1.8. Hemostemix Inc.
  • 13.1.9. Jasper Therapeutics, Inc.
  • 13.1.10. NOVADIP Biosciences S.A.
  • 13.1.11. Novartis AG
  • 13.1.12. Opexa Therapeutics, Inc.
  • 13.1.13. Regeneus Ltd.
  • 13.1.14. Takeda Pharmaceutical Company Limited
• 13.2. Key Product Portfolio

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing